Evaluation of cold-recombinant influenza A/Korea (CR-59) virus vaccine in infants.
Twenty-four infants 5 to 13 months of age were intranasally vaccinated with a live cold-recombinant influenza A/Korea (CR-59, H3N2) virus vaccine. Nineteen infants served as controls. The inocula ranged from 10(3.2) to 10(6.2) 50% tissue culture infective doses (TCID50) per infant. Zero of six, one of four, seven of ten, and four of four infants receiving 10(3.2), 10(4.2), 10(5.2), and 10(6.2) TCID50, respectively, were infected by the intranasal vaccine. The amount of virus required to infect 50% of infants was calculated to be 10(4.6) TCID50. The occurrence of fever, respiratory illness, and otitis media was common among both controls and vaccinees in the postinoculation period. Maternal antibody was present in low titers in some infants and did not inhibit replication of the vaccine virus.
Anderson
E L
EL
Department of Medicine, Marshall University School of Medicine, Huntington, West Virginia 25755-9410.
Belshe
R B
RB
Burk
B
B
Bartram
J
J
Maassab
H F
HF
D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D004797:Enzyme-Linked Immunosorbent Assay; D005289:Ferrets; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007223:Infant; D009980:Influenza A virus / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D010641:Phenotype; D013696:Temperature; D014614:Vaccines, Synthetic; D010948:Viral Plaque Assay
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic